Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis
American Journal of Psychiatry
Fecha de publicación: 5 december 2018
DOI: https://doi.org/10.1176/appi.ajp.2018.17121363
Autores: Jian-Ping Zhang , M.D., Ph.D., Delbert Robinson , M.D., Jin Yu , M.S., Juan Gallego , W. Wolfgang Fleischhacker , M.D., Rene S. Kahn , M.D., Benedicto Crespo-Facorro , M.D., et al.
Background: Pharmacogenomic studies of antipsychotics have typically examined effects of individual polymorphisms. By contrast, polygenic risk scores (PRSs) derived from genome-wide association studies (GWAS) can quantify the influence of thousands of common alleles of small effect in a single measure. The authors examined whether PRSs for schizophrenia were predictive of antipsychotic efficacy in four independent cohorts of patients with first-episode psychosis (total N=510).
